Frontlight ResearchEarly access
Psoriasis trials in China
38 of 48 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleTo Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
- Where
- Wuhan
- Age
- 18 years to 70 years
- People
- 24
- Run by
- Ganzhou Hemay Pharmaceutical Co., Ltd
See details and how to joinNCT06376474 - No phaseTaking peopleA Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 140
- Run by
- Usynova Pharmaceuticals Ltd.
See details and how to joinNCT07234591 - Phase 1Taking peopleA Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
- Where
- Hangzhou
- Age
- 18 years to 55 years
- People
- 124
- Run by
- Usynova Pharmaceuticals Ltd.
See details and how to joinNCT07038720 - Phase 2Not yet taking people in ChinaA Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 150
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07150988 - Phase 2Not yet taking people in ChinaA Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
- Where
- Beijing
- Age
- 6 years to 17 years
- People
- 20
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07102888 - Phase 1Taking peopleEvaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118
- Where
- Hangzhou
- Age
- 18 years to 65 years
- People
- 142
- Run by
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07033234 - Phase 3Enrolling by invitationSulodexide in Controlling the Recurrence of Psoriasis
- Where
- Xi'an
- Age
- 18 years to 65 years
- People
- 160
- Run by
- Xijing Hospital
See details and how to joinNCT06982196 - Phase 2Not yet taking people in ChinaA Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 305
- Run by
- Hansoh BioMedical R&D Company
See details and how to joinNCT06926582 - Phase 2Taking peopleA Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
- Where
- Nanjing
- Age
- 18 years to 70 years
- People
- 140
- Run by
- Zhejiang Wenda Pharma Technology LTD.
See details and how to joinNCT06912165 - Phase 2Taking peopleEfficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
- Where
- Beijing, Shanghai
- Age
- 18 years to 75 years
- People
- 33
- Run by
- Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT06231381 - Phase 3Not yet taking people in ChinaThe Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
- Where
- Beijing, Shanghai
- Age
- 6 years to 18 years
- People
- 90
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06833307 - Phase 4Not yet taking people in ChinaPhase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
- Where
- Beijing
- Age
- 18 years and over
- People
- 1,564
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06779097 - No phaseTaking peopleImmunoclassification of Psoriasis: a Strategy for Precision Medicine
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05503875